arrow
A

Arántzazu Barquín

medical oncology
H指数:10
被引数:324

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Progression free survival as a surrogate of overall survival in metastatic or recurrent endometrial cancer: an EORTC Gynaecologic Cancer Group study

无进展生存期作为晚期或复发性子宫内膜癌总生存期的替代指标:一项EORTC妇科肿瘤组研究

2025-08-190
PRE
The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third- line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial

mirvetuximab soravtansine在FRα阳性、三线及以后、复发性铂敏感卵巢癌中的疗效与安全性:单臂II期PICCOLO试验

2025-03-010
OAAI
Proteomic profiles of peritoneal fluid-derived small extracellular vesicles correlate with patient outcome in ovarian cancer

腹膜液来源的小细胞外囊泡的蛋白质组学特征与卵巢癌患者预后相关

2024-04-023
OAAI
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme

维持尼拉帕尼治疗铂类敏感性复发性卵巢癌的真实世界安全性和有效性: 西班牙扩大访问计划中的GEICO回顾性观察研究

2023-03-016
OA
Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study
2022-11-088
OAAI
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma

MCM3是一种与输卵管卵巢高级别浆液性癌患者生存期延长相关的新型增殖标志物

2021-11-1510
OA